Shield screening volume more than tripled, but Guardant now expects $205 million to $220 million of 2026 cash burn.
Guardant Health Inc (GH) posted $361 million in Q3 2026 revenue, driven by explosive Shield adoption and oncology volume growth, while raising full-year guidance to $1.36-$1.37 billion.
Guardant Health (GH) delivered earnings and revenue surprises of 0.00% and +2.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Shares of both plummeted following their third-quarter reports.
Guardant Health (GH) has drawn fresh attention after appointing Kevin Sayer, former Dexcom CEO and current Executive Chairman, to its board of directors. The move is raising new questions about where the stock’s story goes next. Guardant Health’s share price has pulled back in the short term, with a 1-day share price return of down 3.67% and a 7-day share price return of down 9.03%, even as the year-to-date share price return of 65.70% and a 1-year total shareholder return of 75.15% point to...
Guardant Health reported that its Shield blood test for colorectal cancer screening received the 2026 Prix Galien USA Award for Best Medical Technology, recognizing the first FDA approved blood test for primary colorectal cancer screening and its role in raising screening participation and adherence in real world use. The company also added Kevin Sayer, former Dexcom CEO and current Executive Chairman, to its board. This brings deep digital health operating experience and governance insight...
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Natera is Thursday's IBD Stock Of The Day. Shares are hovering around their 21-day line, taking a breather after running up.
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
PALO ALTO, Calif., October 20, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Mad
This is the newest page. Registered accounts read further back.